Filtros : "LAURETTI, GABRIELA ROCHA" "ANALGÉSICOS" Removido: "ESPECTROMETRIA DE MASSAS" Limpar

Filtros



Refine with date range


  • Source: Fundamental and Clinical Pharmacology. Unidades: FMRP, FCFRP

    Subjects: ANALGÉSICOS, CITOCROMO P-450, ESTEROIDES

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      MORAES, Natália V. de et al. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. Fundamental and Clinical Pharmacology, v. 30, n. 2, p. 153-161, 2016Tradução . . Disponível em: https://doi.org/10.1111/fcp.12168. Acesso em: 01 out. 2024.
    • APA

      Moraes, N. V. de, Lauretti, G. R., Coelho, E. B., Godoy, A. L. P. C., Neves, D. V., & Lanchote, V. L. (2016). Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. Fundamental and Clinical Pharmacology, 30( 2), 153-161. doi:10.1111/fcp.12168
    • NLM

      Moraes NV de, Lauretti GR, Coelho EB, Godoy ALPC, Neves DV, Lanchote VL. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain [Internet]. Fundamental and Clinical Pharmacology. 2016 ; 30( 2): 153-161.[citado 2024 out. 01 ] Available from: https://doi.org/10.1111/fcp.12168
    • Vancouver

      Moraes NV de, Lauretti GR, Coelho EB, Godoy ALPC, Neves DV, Lanchote VL. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain [Internet]. Fundamental and Clinical Pharmacology. 2016 ; 30( 2): 153-161.[citado 2024 out. 01 ] Available from: https://doi.org/10.1111/fcp.12168
  • Source: Journal of Pharmacy and Pharmacology. Unidades: FMRP, FCFRP

    Subjects: DIABETES MELLITUS, FARMACOCINÉTICA, ANALGÉSICOS, DOR, NEUROPATIAS DIABÉTICAS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      MORAES, Natália Valadares de e LAURETTI, Gabriela Rocha e LANCHOTE, Vera Lúcia. Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers. Journal of Pharmacy and Pharmacology, v. 66, n. 9, p. 1222–1230, 2014Tradução . . Disponível em: https://doi.org/10.1111/jphp.12255. Acesso em: 01 out. 2024.
    • APA

      Moraes, N. V. de, Lauretti, G. R., & Lanchote, V. L. (2014). Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers. Journal of Pharmacy and Pharmacology, 66( 9), 1222–1230. doi:10.1111/jphp.12255
    • NLM

      Moraes NV de, Lauretti GR, Lanchote VL. Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers [Internet]. Journal of Pharmacy and Pharmacology. 2014 ; 66( 9): 1222–1230.[citado 2024 out. 01 ] Available from: https://doi.org/10.1111/jphp.12255
    • Vancouver

      Moraes NV de, Lauretti GR, Lanchote VL. Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers [Internet]. Journal of Pharmacy and Pharmacology. 2014 ; 66( 9): 1222–1230.[citado 2024 out. 01 ] Available from: https://doi.org/10.1111/jphp.12255

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024